Karyopharm Therapeutics Inc KPTI
News
Karyopharm to Present Selinexor Data in Patients with Myelofibrosis and Multiple Myeloma at the 68th American Society of Hematology Annual Meeting and Exposition (ASH)
Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Trading Information
- Previous Close Price
- $0.06
- Day Range
- $0.04–0.06
- 52-Week Range
- $0.04–10.99
- Bid/Ask
- $0.04 / $0.04
- Shares Outstanding
- 22.68M
- Market Cap
- $1.25M
- Volume/Avg
- 539,821 / 6M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.01
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 228
- Website
- https://www.karyopharm.com
Valuation
Metric | KPTI |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.01 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | KPTI |
|---|---|
Quick Ratio | 0.71 |
Current Ratio | 0.79 |
Interest Coverage | −3.61 |
Quick Ratio
KPTI
Profitability
Metric | KPTI |
|---|---|
Return on Assets (Normalized) | −106.81% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
KPTI
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|?Hn%jm | LOCK|v%%? | $139B | |||
| Moderna Inc MRNA | LOCK|gy%^?&z | LOCK|G<t | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|@g>!!^m | LOCK|#v>Q | $94B | |||
| argenx SE ADR ARGX | LOCK|KC>ZNJ | LOCK|%N | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|Mpl@yJ | LOCK|&Q | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|$<Ry>!kM | LOCK|c<!yW | $30B | |||
| Incyte Corp INCY | LOCK|HtkmFg | LOCK|h?v | $24B | |||
| BioNTech SE ADR BNTX | LOCK|ns>R$r | LOCK|tQ& | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|!#QKy>& | LOCK|%#<J! | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|^V$P&L# | LOCK|q&m | $15B |
United States